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Background
To study the meaning of HIV indeterminate serology
(HIVi), evaluating the deferral criteria of HIV screening
test, we looked for donors (D) whose blood donations
(BD) were discarded for HIVi from 1/1/1999 till 31/12/
2005. The test system of blood donations is Prism Abbott
Anti-HIV 1/2; HIV supplemental test was New Lav-Blot I/
II-Bio-Rad till 2002 and Inno-Lia™ HIV I/II-Innogenetics
afterwards. We perform a NAT test in all single donation
since 2000, detecting HIV-1 and HCV RNA; since 2/2004
we perform Procleix® Ultrio™ Assay. Grey zone (GZ) for
HIV screening test means 20% inferior to the cutoff
(ICO). D that have been deferred for HIV serology but
didn't obey to these criteria were excluded.
Results
In seven years, we find in a body of 25 024 D, 145 with
HIVi; 8 were excluded and 18 had no follow-up. 64 D
showed a confirmed result and 55 D didn't confirm. 77
cases had the supplemental test negative, 52 showed an
indeterminate pattern and one a positive pattern. This
case became negative after 1 year of follow-up. None of D
seroconverted. 50 cases of the indeterminate supplemen-
tal test have occurred before 2002. None of BD or D had
a reactive NAT test. The ICO value showed a direct relation
with the confirmation rate.
Conclusion
We found 0,58% indeterminate HIV donors, 41,6% in GZ
ICO and 54% didin't confirm. ICO hadn't shown predic-
tive value for HIV infection. A positive supplemental test
in a low prevalence population may not correspond to
HIV infection. Inno-Lia™ HIV I/II showed a specificity of
92,9% compared to 47,4% of New Lav-Blot I/II. GZ in
anti-HIV test hasn't brought more security. There isn't
HIV-1 infection without a NAT test reactive and we save
23,8% of HIVi donors.
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